Меню
Идёт набор NCT07561203

Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.

Без фазы С лечением Healthy Adult Male

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Native type II collagen (Collavant® n2), Placebo.
Кому может быть актуально
Состояния в реестре: Healthy Adult Male. Базовые параметры: 40 лет — 65 лет · Мужчины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Испания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Effect of Collavant® n2 on Joint Function and Performance in Healthy, Active Male Adults With Exercise-induced Joint Discomfort.

Обзор

The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.

Подробное описание

The COLLMOTION study is a randomized, double-blind, placebo-controlled, parallel clinical study designed to evaluate the effects of Collavant® n2 on joint function, performance and discomfort in healthy, physically active male adults experiencing exercise-induced knee discomfort.

A total of 80 healthy male amateur runners aged 40 to 65 years are enrolled and randomized in a 1:1 ratio to receive either Collavant® n2 (40 mg/day) or placebo for a total intervention period of 24 weeks. Eligible participants are required to train regularly (≥150 minutes per week), report persistent exercise-related knee discomfort, and meet predefined inclusion and exclusion criteria to ensure the absence of diagnosed knee pathology such as osteoarthritis.

The primary objective of the study is to assess differences from baseline and versus placebo in joint discomfort. Secondary objectives include the evaluation of joint function, physical performance, perceived exertion, pain intensity before exercise, time to pain recovery, and joint inflammation.

Safety and tolerability are evaluated throughout the study via monitoring of adverse events, vital signs, physical examinations, laboratory parameters, and quality-of-life assessments. Participants undergo assessments at baseline, 12 weeks, and 24 weeks.

Вмешательства

  • Пищевая добавка Native type II collagen (Collavant® n2)
    Native type II collagen (Collavant® n2). 1 capsule 40 mg / day
  • Другое Placebo
    Placebo. 1 capsule / day

Первичные конечные точки

  • Change in Exercise-Induced Knee Joint Discomfort [Срок оценки: Baseline (week 0) to week 24]
Вторичные конечные точки (8)
  • Change in joint pain intensity after physical activity [Срок оценки: Baseline (week 0) to week 12]
  • Change in joint pain intensity before physical activity [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Time to recovery of knee pain after exercise [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Change in physical performance during the running test [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Change in perceived exertion during physical activity [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Change in knee joint function [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Change in knee joint inflammation [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]
  • Change in cartilage biomarkers [Срок оценки: Baseline (week 0) to week 12, baseline (week 0) to week 24]

Критерии участия

Критерии включения

  • Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years
  • Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms.
  • Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w.
  • Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period.
  • Have individual devices to monitor training with GPS
  • Sign informed consent

Критерии исключения

  • Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee.
  • Hypersensitivity to any component of the supplement or the placebo
  • Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs
  • Treatment with any type of collagen supplement
  • Treatment with probiotics or antibiotics
  • Inability to train for the next 24 weeks
  • Follow a vegan diet

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Другое

Центры проведения

Испания · 1 центр
  • Universidad Politecnica de Madrid — Madrid

Идентификаторы

NCT: NCT07561203 · PJ-00186 / COLLMOTION · PJ-00186 / COLLMOTION

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗